Abstract: Stereochemistry is one of the essential dimensions in pharmacology as it dictates how enantiomers interact with biological systems. Chirality is very important in drug design. Enantiomers of the same chiral drug can have different pharmacodynamic and/or pharmacokinetic properties. In this context, replacing some existing racemates with single isomers has resulted in improved safety and/or efficacy profile of various racemates. Single enantiomer drug use can potentially lead to simpler and more selective pharmacologic profiles, improved therapeutic indices, simpler pharmacokinetics due to different rates of metabolism of the different enantiomers, decreased drug interactions, and drug companies are increasingly using chiral switching as a marketing strategy. Additionally, due to different pharmacological activity, enantiomers of chiral drugs can differ in toxicity. However, unpredicted toxicity has been reported in some chiral switching cases which has resulted the withdrawal of the enantiomer from the market or a halt in its development. In view of above, before switching to single enantiomer drugs, prescribers should look for evidence from well-conducted clinical trials to prove that the chiral switch is cost-effective and improves the outcomes for patients rather than patents. The U.S. Food and Drug Administration (FDA) have allowed single enantiomers of generic drugs to be patented and marketed under different name. FDA regulations require that all chiral bioactive drug molecules must be isolated and tested for the efficacy and safety, and have to be as pure as possible containing a single pure enantiomer.
INTRODUCTION
Chiral drugs continue to be a significant force in the global pharmaceutical market as chirality significantly influences a drug's biological and pharmacological properties. Stereochemistry impacts decisions made in the absorption, distribution, metabolism, excretion, and toxicity stages of drug discovery [1] . Stereoselective methods have been employed to study enantioselective metabolic profiling of the active components from Herbal Medicines in vitro and in vivo in recent years [2] . Chiral drugs make up 40-50% of the market today. The extension of patent protection for drugs manufactured from enantiomers is an important factor that is driving growth of chiral intermediates in pharmaceuticals. For some drugs, only one enantiomer is effective that would, in theory, only require half the effective dose of a 50/50 racemic mixture. In this context, chirality has become a major theme in the design, discovery, development and marketing of new drugs [3] [4] [5] . Enantiomers of a chiral drug may work differently in the body [6] . The observed differential antioxidant, but comparable antiinflammatory activities may explain the stereospecific antiischemic activities and different therapeutic time windows of the transand cis-hinokiresinols which possess anti-oxidant, antiinflammatory and estrogen-like activities. Further, *Address correspondence to this author at the PCTE Institute of Pharmacy, Jhanday, near Baddowal Cantt, Ludhiana-142 021, India; Tel: 911612888550; Fax: 911612888505; E-mail: sekhon224@yahoo.com trans-hinokiresinol possesses extended profiles in antioxidant activity than cis-isomer whereas both hinokiresinols can modulate the inflammatory response [7] . The choice between single stereoisomers (homochiral drugs) and composite chiral drugs (mixtures of stereoisomers) depends upon therapeutic advantages (such as a reduction in xenobiotic load), possible adverse side-effects and development costs. Most illicit drugs are chiral compounds. There is a need for continuous evaluation of existing and new composite chiral drugs. This article focuses on chiral/single enantiopure drugs in relation to pharmacology.
Drugs are classified into achiral, racemic and singleenantiomer (enantiopure) drugs with one-chiral center or multi-chiral centers. An enantiopure drug is a pharmaceutical that is available in one specific purified enantiomeric form. Most commonly, drugs containing a single asymmetric carbon atom exist in two enantiomeric forms, designated as eutomer (the more potent) and distomer (the less potent). Living organisms are made up of chiral, enantiomerically pure compounds. For example, most amino acids in the proteins of all living organisms have the absolute (S)-configuration. Enantiomers of drugs often have greatly different affinities at receptor sites, are metabolised at different rates, and have different affinities for tissue and protein binding sites [6] . Despite this knowledge, many drugs are administered as their racemates. "Chiral switch" used to transform an old racemic drug into its single active enantiomer can be used to extend the patent life of a drug and assign a new generic name or in developing new blockbusters for Pharma companies. Drug companies also develop ways to purify one enantiomer and provide a medication using only that enantiomer. Single stereoisomer drugs would provide superior therapy by allowing reductions in dosage, reduced variability in metabolism and response, simpler dose-response relationships and improved tolerability [8] . Many enantiopure drugs offer clinical advantages over the racemic forms. One enantiomer of a chiral drug may have a desired beneficial effect while the other may be inactive, or cause serious and undesirable side effects, or sometimes even entirely different effects [9] .
CHIRALITY
Isomers are compounds with the same molecular formula but different structural formulas. There are two major categories of isomers: constitutional (or structural) isomers and stereoisomers. Constitutional isomers are molecules with the same atomic composition but different bonding arrangements between atoms, as illustrated by the examples of catechol, resorcinol, and hydroquinone ( Stereoisomers are molecules with one or more "chiral" centres that allow the possibility of forms with the same chemical formula but differ in spatial arrangement of atoms. They can be classed as cistrans isomers or optical isomers.
The concept of non-superimposable mirror images i.e. chirality is formally defined as the geometric property of molecule or drug of not being superimposable with its mirror image. The human body is chiral, and hands, feet, and ears are not superimposable. As a hand fits a glove, only the "right" or "left" handed enantiomer may fit a molecular receptor at a drug's desired site of action. In the (+/-) system, an enantiomer that rotates light clockwise or counter-clockwise is said to be dextrorotatory [d or (+)], or levorotatory [l or (-)], respectively. All living organisms contain almost only 'left-handed' aminoacids and 'right-handed' sugars. A second difference between enantiomers is their interactions with other chiral substances. For example, enantiomers may have different solubilities in chiral solvents, they may react at different rates in the presence of an optically active reagent or enzyme, and many have different affinities for chiral surfaces and receptors. The D/L system relates the stereochemistry of a molecule to that of a standard reference compound, either the carbohydrate D-glyceraldehyde or the amino acid L-serine. The Cahn, Ingold, and Prelog nomenclature is now employed to assign absolute configuration of the molecular structure of chiral tetrahedral molecules. "R" and "S" refer to the absolute configuration about the "center of asymmetry". In this R/S system, based on the specific atoms in the molecule, one configuration is called "rectus" (R-for short) and the other is called "sinister" (S-for short), from the Latin words for right and left. A racemate is designated as RS [10, 11] . The introduction of chirality in penicillin to obtain ampicillin increases its usefulness to kill bacteria that have developed a resistance to penicillin.
The drug methamphetamine has a chiral centre (an asymmetric carbon atom attached to four different substituents) giving rise to two stereoisomers (spatial isomers), known as optical isomers, which are mirror images of each other. On the other hand, aspirin is achiral. The structures of the optical isomers of methamphetamine (chiral) and aspirin (non-chiral) are shown in Figure 2 .
Enantiomers have two non-superimposable mirrorimage forms, for example, S-Fluoxetine and RFluoxetine (Figure 3) . Most chiral drugs contain one or more chiral centers. Natural compounds are often single enantiomers (e.g. morphine, epinephrine, hyoscine, levothyroxine, levodopa, l-noradrenaline, (-)-brucine) [12, 13] . In contrast, many commercially synthesized drugs are racemic mixtures (e.g. ibuprofen, atenolol, adrenaline, warfarin, fluoxetine, omeprazole) but there is an increasing trend for the pharmaceutical industry to develop and market products containing only the leftor right-handed molecule [14] . Ibuprofen enantiomers are based on carbon stereogenic center.
Thalidomide (Figure 4) is one chiral center hypnotic and anti-nausea drug. The R-enantiomer is an effective sedative that relieves anxiety and promotes sleep. However, the S-enantiomer may cause teratogen formation. It is important to mention that S-thalidomide was shown to be responsible for over 2,000 cases of serious birth defects in children born of women who took it during pregnancy [15] . Sulfur, phosphorus and nitrogen can sometimes form chiral molecules such as omeprazole, cyclophosphamide and methaqualone, respectively [16] . Enantiomers based on phosphorus chiral center may include phosphine, phosphine oxide, phosphinate and phosphonium ion. The antineoplastic agent cyclophosphamide is one example of a compound with a chiral phosphorus moiety [16] (Figure 5 ). It is converted in the liver to active forms that have chemotherapeutic activity. The main use of cyclophosphamide is with other chemotherapy agents in the treatment of lymphomas, some forms of brain cancer, leukemia [17] and some solid tumors [18] . Ifosfamide is a nitrogen mustard alkylating agent used in the treatment of cancer (Figure 6 ). 
2a. P-Chiral Nucleotide Prodrugs
PSI-7977's ( Figure 7 ) is a nucleotide strapped on to a phosphoramidate P-chiral prodrug, a "protected" substance which is later converted by the body to the active drug species [19] . PSI-352938 (Figure 8 ) is a novel cyclic phosphate prodrug of -D-2'-deoxy-2'--fluoro-2'--C-methylguanosine-5'-monophosphate that has potent activity against hepatitis C virus (HCV) in vitro [20, 21] .
Enantiomers based on sulfur may include sulfoxide, sulfoximide, sulfinate and sulfoniumion. Enantiomers based on nitrogen may include amine oxide and ammonium ion. The sulfur atom of the nonsteroidal antiinflammatory sulindac (Figure 9 ) bears four different substituents (one being a pair of electrons) and hence is chiral. Omeprazole (Figure 10) is an example of a stereogenic sulfur atom. Esomeprazole (S-enantiomer of omeprazole) is chiral drug which is used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease and Zollinger-Ellison syndrome. Armodafinil (Nuvigil) is a stimulant-like enantiopure drug consisting of just the active ( )-(R)-enantiomer of the racemic drug Modafinil (Provigil) (Figure 11 ). This drug was produced by the pharmaceutical company Cephalon Inc., and was approved by the FDA in 2007 [22] . [23] . A racemate (racemic mixture) represents 1:1 (equimolar, e.e.= 0) mixture of enantiomers. Most illicit drugs are chiral compounds. S(+)-amphetamine has twice as high stimulant activity as R(-)-amphetamine. The verification of enantiomeric ratios for chiral drugs that include amphetamine, methamphetamine, MDMA, MDEA, MDA, ephedrine and pseudoephedrine can provide vital information about patterns of drugs usage and can help in the differentiation between their legal and illicit usage [24] .
POTENTIAL ADVANTAGES OF ENANTIOPURE DRUGS
Potential advantages of single-enantiomer drugs include: separating unwanted pharmacodynamic side effects from toxic effects in case these reside exclusively in one enantiomer, smaller doses of medication; simpler and more selective pharmacodynamic profile; less complex pharmacokinetic profile; less side-effects because of the elimination of distomers; reduce drug interactions, fewer adverse effects, one form is more prone to adverse drug interactions; reduced metabolic load over the enzymatic system; potential for an improved therapeutic index and less complex relationship between plasma concentration and effect [25] [26] [27] . Further, the advantages of enantiopure drugs over racemic drugs have varied, depending on the case, and the biological effects of single enantiomer drugs over their counterpart racemic drugs still remain unclear in some cases.
3a. Purification and Downstream Processing Strategies
The future of biomanufacturing industry is based on the technology trends in downstream purification processes/bioprocess which are gaining importance as biologic drugs has high potential for future growth because of improvements in cost-effective purification technologies. The goal of the purification strategies is to develop scalable downstream processes for the purification of biopharmaceutical products. Downstream processing is an essential step in the manufacture of pure pharmaceuticals particularly therapeutic protein drug and biopharmaceuticals (e.g. monoclonal antibody), antibiotics, hormones (e.g. insulin and human growth hormone), vaccines, and enzymes used in diagnostics with high yield as priorities generally in marketable quantities [28] .
In the downstream phase of manufacturing, the protein product is isolated from the cells that produced it. Special protocols are required to extract intracellular proteins for purification. Usually this involves bursting the cells open to release the protein product, which then has to be purified away from the other components that were inside the cell. In this context, extracellular proteins are easier to isolate. After harvesting the protein product, clarification process separate the protein from cellular debris. Then the protein solution is subjected to a series of chromatography columns where a pure protein product is obtained based on physical and chemical properties such as size, shape or charge (+ or -) of protein.
Additional purification steps are required to remove any residual DNA and deactivate any viral particles that may be present.
Stages in downstream processing include: target contaminants, a capture section (removal of insolubles), concentration, capture/initial purification, intermediate purification, final purification and sterilization/formulation. Large-scale chromatography operations continue to occupy a key position in the overall strategy for the downstream processing and purification of protein products for therapeutic use. Affinity, cation-exchange, anion-exchange, ceramic hydroxyapatite, and hydrophobic-interaction membrane chromatography are the main types of chromatography modes used in large-scale bioseparations [29, 30] . Affinity chromatography (a single step purification step) was applied for the purification of monoclonal antibodies [31] . The application of partition designs to a monoclonal antibody purification process was reported [32] . Affinity tags are highly efficient tools for protein purification [33] . A trend from classical purification methods like sucrose gradient centrifugation towards more sophisticated techniques like tangential flow filtration and liquid chromatography is being followed for adenoviruses, adeno-associated viruses or retroviruses [34] . Regarding removal of the host-cell proteins during vaccine purification, the standard purification protocol is based on anion-exchange chromatography followed by cation-exchange chromatography and a final step using hydroxyapatite. Mimetic ligands can be integrated into a purification platform with an affinity capture step that will achieve a high-capacity recovery of the product with excellent removal of host-cell proteins. Integrating tangential flow filtration technology helps overcome the potential bottleneck in capture purification, but it won't replace conventional ultrafiltration for all processes. Disposable technology is increasing in popularity for the final polishing step. Current methodology used in recovery processes for therapeutic monoclonal antibodies was reported [35] . Packed-bed chromatography is the workhorse in the downstream processing of therapeutic monoclonal antibodies. Convective Interaction Media DEAE columns have shown to be a good alternative for the purification of lentiviral vectors which hold great potential as gene delivery vehicles [36] . Cibracon Blue dye resin, a polycyclic anionic ligand, was used to effectively and efficiently separate an IgG4 MAb from host and process impurities following the capture of the MAb on a Protein-A (PA) column [37] .
Researchers successfully generated pure biotinylated full-length DENV C protein with an optimized sequential purification protocol involving nickel-nitriloacetic acid affinity chromatography, dialysis, ion exchange-fast protein liquid chromatography and size exclusion chromatography. This purified non-truncated DENV C protein was found suitable for structural and molecular studies [38] . In pharmaceutical industries, downstream processing has an influence on active pharmaceutical ingredients (API) crystals whose properties must be controlled because they influence the end-use properties of the drug. Filter cake washings has been used to remove all the impurities and to obtain a pure crystalline crystal form of API [39] .
3b. Enantiopure Drugs Preparation
The separation of enantiomers is called resolution which is essential in order to ensure the safety and efficiency of chiral compounds. Nowadays, the technologies of resolution and asymmetric synthesis have advanced to the point that the cost of making enantiopure material is not so great, and the FDA is expressing a strong preference that all medicinal drugs are sold in enantiopure form. Drug companies develop ways to obtain one enantiomer and produce a Anticholinergic trihexyphenidyl, benztropine, procyclidine, biperiden, ethopropazine, diphenhydramine and orphenadrine medication using only that enantiomer. Three strategies can be applied to obtain single pure isomers: (i) extraction from plants and animal materials (ii) enantio-selective asymmetric synthesis so that only one isomer is formed in the first place [40] or (iii) making a racemate and finding a method for separating the enantiomers (chiral resolution) [41] [42] [43] . Among the variety of enantioseparation methods, classical resolution [44] , Simulated Moving Bed technology [45] , chiral chromatography and crystallization are the most dominant methods for the recovery of pure enantiomers [46, 47] . The performance of the hybrid SMB-crystallization process was reported for the chiral resolution of mandelic acid as racemic compound [48] . Biocatalysis synthesis routes are also the choice to obtain enantiopure drug. Various enzymes like oxidoreductase, transferase, hydrolase, lyase, isomerase and lipases act on the different prochiral or racemic compounds to yield chirally pure drugs/precursors [49] . The preparation of the enantiopure drug Clopidogrel has been achieved by the employment of the resolution technique called attrition-based deracemisation [50] .
REPRESENTATIVE CHIRAL DRUGS
Examples of chiral drugs from various therapeutic classes are given in Table 1 .
Annual new drug approvals of racemic and enantiopure drugs have been consistently published by the US Food and Drug Administration [55] . Albendazole is an anthelmintic drug widely used in the treatment of neurocysticercosis, an infection of the brain with Taenia solium cysts. Use of (+)-(R)-Albendazole sulfoxide (Figure 12 ) enantiomer alone may lead to increased efficacy and/or less toxicity compared to albendazole [59] . Mephedrone ( Figure 13 ) most probably as a racemic mixture of the R and S enantiomers is a synthetic psychoactive substance. This drug has been readily available for legal purchase both online and in some stores and has been promoted by aggressive Web-based marketing. Its abuse in many countries, including the United States, is a serious public health concern. Mephedrone has been sold as a 'legal' alternative to 'ecstasy', amphetamines and cocaine. It was first detected in November 2007 and notified via the EMCDDA's Early Warning System in March 2008. Evidence of mephedrone use and associated toxicity has been increasing, in 2009 and 2010 [60] . USA temporarily classified mephedrone as illegal, in effect from October 2011. Only little is known about the pharmacology of Mephedrone (4-methylmethcathinone). The S form is thought to be more potent than the R form, because this applies to cathinone [61] . Mephedrone has a unique pharmacological profile with both abuse liability and neurotoxic potential [62] . Fenoldopam ( Figure 14) is a dopamine D1 receptor agonist that is used as an antihypertensive agent [63] . Fenoldopam is a racemic mixture of two enantiomers, SK&F R-82526 and SK&F S-82526. The results showed that the renal and systemic vasodilator activities of fenoldopam are properties of the Renantiomer via stimulation of postganglionic DA-1 receptors; the S-enantiomer is essentially inactive [64] . . This is a new treatment for multidrug-resistant tuberculosis that can be used as an alternative when other drugs fail [65] . Further study is desired to assess relative activity of both enantiomers. Thioctic acid (Figure 18) , also known as alpha-lipoic acid (1,2-dithiolane-3-pentanoic acid), is a naturally occurring antioxidant that neutralizes free radicals in the fatty and watery regions of cells. Mefloquine (Figure 19 ) is currently manufactured and sold as a racemate of the (R,S)-and (S,R)-enantiomers by Hoffman-LaRoche, a Swiss pharmaceutical company. Essentially, it is two drugs in one. (+)-Mefloquine is more effective in treating malaria, and the (-)-Mefloquine specifically binds to adenosine receptors in the central nervous system, which may explain some of its psychotropic effects [67] . The stereospecificity of S-Ropivacaine decreases cardiotoxicity [68] .
The name, nature, number of chiral atoms and activity of some other representative chiral drugs (racemate and enantiopure) are given in Table 2 .
PHARMACOLOGICAL DIFFERENCES BETWEEN TWO ENANTIOMERS OF A CHIRAL DRUG
The human body is a highly complex chiral environment. After chiral drugs affect the body, two enantiomers bound to macromolecular show differences in aspect of mechanism and integration, thereby, resulting in the stereoselectivity characteristics of the chiral drug and differences in pharmacology. The pharmacodynamic properties of drugs describe their interactions with selective targets on the body, including transport proteins, tissue and blood plasma proteins, enzymes and receptors, steroids, doseresponse phenomena, and mechanisms of therapeutic and toxic action [69] . Pharmacokinetics (described as what the body does to a drug) refers to the time course of the various events that a drug and its metabolites undergo in the body, such as absorption, distribution, metabolism and excretion. There are multiple examples of varied receptor types with chiral dependence. However, the magnitude of the differences between a pair of enantiomers in their pharmacokinetic parameters tends to be relatively modest in comparison to their pharmacodynamic properties [70] . Stereoselective metabolism of drugs is most commonly the major causative factor to stereoselectivity in pharmacokinetics as metabolizing enzymes often exhibit a preference for one enantiomer of a chiral drug over the other [71, 72] . The structural characteristics of enzymes dictate the enantiomeric discrimination related with the metabolism of chiral drugs [73] . The clinical pharmacology of chiral drugs is based on understanding the nature of pharmacodynamics and pharmacokinetics important differences for the optimization of pharmacotherapy [74] . between bovine serum albumin and human serum albumin while stereo-selectivity was identical between human serum albumin and human plasma [75] . Based on Easson-Stedman Principle with three-point binding model [76] , only one enantiomer binds to enzyme & desired reaction occurs (Figures 20 and 21) .
Mesecar and Koshland model reveals that a fourth location, either a direction requirement or an additional binding site, is essential to distinguish between a pair of enantiomers. Further, that the three-point model is only applicable if the assumption is made that the substrate can approach a planar surface from one direction [77] . (S)-Naproxen is common over-thecounter pain reliever and it binds to the enzyme cyclooxygenase and inhibits its action in the synthesis of prostaglandins. Only the (S)-naproxen isomer will bind to and inhibit the cyclooxygenase enzyme to decrease prostaglandin production. Decreasing prostaglandin production at the site of injury decreases pain and inflammation [78] . Naproxen (Figure 22 ) is a promising lead compound for novel antivirals against influenza A virus that targets the nucleoprotein in its RNA binding groove [79] ; however, it is not known whether both or only one enantiomers is responsible for this reaction. (R)-Naproxen does not inhibit the cyclooxygenase enzyme and it is toxic to the liver. The structural difference is due to the different arrangement of groups (H-, H 3 C-, HOOC-)-surrounding the central carbon stereocenter. In specific cases, both mirror-image forms of a particular compound can bind at the same time in the same site of an enzyme. The arrangement of the molecules within the binding site was found quite different when both bind together. This could lead to cooperative effects, producing either an enhanced or diminished response relative to the individual enantiomers [80] . The hyptonic effect of zopiclone and eszopiclone results from their interaction with theaminobutyric acid receptors. This leads to an increase in chloride transmission that subsequently depresses the cental nervous system, slowing brain activity, and promoting sedation. Eszopiclone's affinity for this receptor complex has been shown to be twice that of its racemic parent, while the leavorotatory isomer affinity for these receptors is negligible [81] .
Langmuir monolayer technique is a powerful method to discriminate between local anaesthetic (R)-and (S)-enantiomer articaine interaction with model membranes [82] . The above mentioned variations in behaviour of both enantiomers may guide to differences in pharmacology, pharmacokinetics, therapeutic effect, efficacy, and toxicity [83] [84] [85] [86] . Drug therapies illustrating the clinical importance of chirality and stereochemistry have been reported [87] [88] [89] . The difference between enantiomers can mean a difference between therapeutic and adverse effects, as well as in beneficial pharmacological effect and potency [90] [91] [92] . Validated bioanalytical methods should always be used for measurement of individual enantiomers in bioequivalence studies when the enantiomers exhibit different pharmacodynamic characteristics [93, 94] . 
Pharmacodynamic Implications of the Concept of Chirality in Drug Activity
Racemic drugs activity can be divided into different groups (Figure 23, Tables 3-7) . The majority of racemic pharmaceuticals have one major bioactive enantiomer (eutomer) and a less bioactive enantiomer (distomer) [11] .
Examination of the pharmacodynamic properties of a pair of enantiomers may yield a number of possible scenarios: i).
Examples where one enantiomer is 'active', while the other enantiomer is "inactive.
This category includes a number of cardiovascular drugs, agents widely used for the treatment of hypertension, heart failure, arrhythmias, and other diseases ( Table 3) .
ii).
Examples where one isomer is more potent than the other (Table 4) .
iii). Examples of beneficial effects in one enantiomer whilst the other enantiomer has adverse activity ( Table 5 ).
iv).
Where enantiomers have entirely different therapeutic possibilities (Table 6 ).
v) The beneficial effects reside in one enantiomer, the other enantiomer having antagonistic activity ( Table 7) .
vi).
Both enantiomers having equal therapeutic potency/equally biologically active ( Table 8) .
Enantiomers of antiarrhythmic drugs (flecainide, mexiletine, tocainide, propafenone) and antimalarials (mefloquine, halofantrine, enpiroline) have small or no differences in their potency. Only some racemic drugs that could belong to this group include cyclophosphamide (antineoplastic), flecainide (antiarrhythmic), fluoxetine (antidepressant) [90] and prometazine (antihistamine) [114] . However, R, R and S, S Tramadol enantiomers contribute to the similar analgesic pharmacological activity via different mechanisms.
Racemic Drugs with Chiral Inversion
Chiral inversion can take place in two ways, unidirectional and bidirectional conversion. Examples of racemic drugs with chiral inversion include oxazepam, lorazepam, temazepam, omeprazole, levobupivacaine, ibuprofen, ketoprofen, fenoprofen, benoxaprophen [115] . 2-Arylpropionic acids (ibuprofen, ketoprofen, fenoprofen, benoxaprophen, etc. and collectively called as profens) undergo unidirectional metabolic bioconversion of the inactive R-enantiomer into the active S-enantiomer [116, 117] 
S-(-)-Betaxolol Praziquantel (R) -(-)-Praziquantel

S(+)-Zopiclone
Ketoprofen (anti-inflammatory effects)
R-Ketoprofen
Methacholine (a parasympathomimetic drug)
S(+)-Methacholine
Felodipine (an oral calcium channel blocker)
S-(-)-Felodipine
Propranolol ( -adrenoceptor antagonist)
S(-)-Propranolol Ofloxacin (antibacterial activity) (S)-(-)-Ofloxacin
Repaglinide ( the treatment of type II diabetes) 
S(+)-Repaglinide Etodolac (NSAID) S-(+)-Etodolac
Ketamine S(+)-Ketamine is an active anesthetic and analgesic Hallucination and agitation is associated with the R(-)-distomer
Penicillamine S-Penicillamine used to treat arthritis R-Penicillamine is toxic Naproxen (S)-Naproxen R-naproxen causes liver poisoning with no analgesic effect.
Ethambutol (S,S)-enantiomer is tuberculostatic (R,R)-enantiomer causes blindness
Thalidomide (R)-enantiomer of thalidomide is effective against morning sickness (S)-enantiomer is teratogenic,
Citalopram
Citalopram is a selective serotonin reuptake inhibitor and the S-enantiomer is responsible for this effect
The R-Citalopram is therapeutically inactive, but displays other effects or side-effects and thalidomide undergo bidirectional chiral inversion whereby the R and S enantiomers undergo racemisation [11] .
PHARMACOKINETIC DIFFERENCES BETWEEN ENANTIOMERS
The processes of absorption, distribution and metabolism are crucial determinants of drug action and can assume equal relevance to the actual biological effect of the drug at its receptor site. Stereoselectivity in pharmacokinetics may be characterized by a measurable difference between enantiomers in a pharmacokinetic parameter. Pharmacokinetic parameters can be divided into different levels of organisation and that the hybrid character of parameters increases with the level of organization that they represent [119] .
i)
Parameters with the highest degree of hybrid character describe the pharmacokinetic behavior of a drug in the whole body (for example systemic clearance, volume of distribution and half-life); ii) At the organ level, pharmacokinetic parameters represent the combined effects of stereoselectivity in each of their component parameters within an organ (for example hepatic metabolic clearance, renal clearance); iii)
At the molecular level, fraction unbound in plasma, intrinsic metabolic formation clearance reflects the selectivity of an endogenous macromolecule for the enantiomers of a chiral drug molecule [120] [121] [122] . Indeed, many studies have demonstrated that stereoisomers of a chiral drug often exhibited pronounced differences in their pharmacokinetic and metabolic profiles both quantitatively and qualitatively [16, 123] . In addition to differences in potency and other pharmacodynamic properties, most members of enantiomeric pairs commonly differ also in their pharmacokinetic profiles [124, 125] . A literature review indicates that stereoselective pharmacokinetics, rather than stereoselective pharmacological activity, is the main cause of differences in clinical efficacy between pure enantiomer and racemic proton-pump inhibitors. The preferred enantiomer of proton-pump inhibitors is not always in the same absolute configuration, i.e., S-form is for omeprazole, pantoprazole and tenatoprazole whereas R-form is for lansoprazole and rabeprazole [126] .
Some specific examples are given below:
i)
The bioavailability of (R)-verapamil is more than double that of (S)-verapamil due to reduced hepatic first-pass metabolism [127] .
ii) The volume of distribution of (R)-methadone is double that of (S)-methadone due to lower plasma binding and increased tissue binding [127] .
iii) The clearance of (R)-fluoxetine is about four times greater than (S)-fluoxetine due to a higher rate of enzyme metabolism [127] .
iv) The renal clearance of (R)-pindolol is 25% less than (S)-pindolol due to reduced renal tubular secretion [127] .
These differences in clearance and volume of distribution translate into differences in half-life. For example the half-life of (S)-fluoxetine is one quarter that of (R)-fluoxetine. In addition, these pharmacokinetic properties can be modified in a stereoselective manner by disease, genetics, ethnicity, age and other drugs. Finally, the enantiomers of some drugs such as warfarin can be metabolised by different enzymes.
v) The R-enantiomer of modafinil, which is used in the drug Armodafinil to treat sleepiness, has been proven to last longer than its counterpart Senantiomer [126] .
vi) Both renal and total clearance and volume of distribution of (S)-(+)-disopyramide were significantly less than those of the R enantiomer after administration of the racemate .
vii)
A superior pharmacokinetic profile, i.e., higher maximal plasma concentrations (C max ) and area under the curve, was observed with (R)-(+)-rabeprazole compared to its (S)-(-)-enantiomer [128] .
viii) (S)-(-)-omeprazole is cleared more slowly and has an improved oral bioavailability (81%-98% vs 35%-65%), leading to the greater inhibition of gastric acid secretion compared to omeprazole.
ix) Both enantiomers of lansoprazole possess equal potency. CYP2C19 genotype influences the disposition of (S)-(-)-lansoprazole to a greater extent than the (R)-(+)-enantiomer, resulting in less interpatient variability in clearance with (R)-(+)-lansoprazole compared to lansoprazole. Therefore, the use of (R)-(+)-lansoprazole alone would be highly desirable for clinical application [128] .
xi) L-dopa is rapidly absorbed from the gut by an active process whereas D-Dopa is slowly [129] .
xii) In the case of indacrinone which is used in the treatment of hypertension and congestive heart failure, the free fractions are 0.9% and 0.3% for the (R)-and (S)-enantiomer respectively [130] .
xii) The (S)-enantiomer of barbiturate hexobarbital has an elimination half-life which is three times longer than that of the (R)-enantiomer as a result of metabolic clearance [131] .
xiii) Renal clearance of [S-(-)-pindolol L-pindolol(a synthetic beta-adrenergic receptor blocking agent used to treat high blood pressure and to prevent angina) is faster than that of R-(+) -Pindolol [132] .
The potential for discrimination between enantiomers at each of these stages is therefore important and highlights the need for stereospecific drug assays [11] . The clinical picture is more complicated. For example, the results of studies of enantiopure escitalopram versus racemic citalopram have mixed results [133, 134] . Armodafinil (Nuvigil), the R-enantiomer of modafinil (Provigil) stays in the body longer than the S-enantiomer, so theoretically, it may work better or longer than racemic modafinil. However, there are no data yet on whether armodafinil actually works better than racemic modafinil. Right-handed" thalidomide stops nausea and vomiting, while "lefthanded" thalidomide causes severe birth defects [135] .
TOXICOLOGY
Many drugs can often be associated with complex pharmacokinetics and observed toxicities compared to drugs that are administrated as a single enantiomer. The various stereochemical aspects associated with the metabolism and toxicity of chiral drugs has been reported [136] . Enantiomers of chiral drugs can differ in toxicity due to different pharmacological activity. Many chiral drugs can often be associated with complex pharmacokinetics and observed toxicities compared to drugs that are administrated as a single enantiomer [137] [138] [139] . In some cases, chiral switching has been of no benefit. For example, the clinical development of (R)-fluoxetine for depression (based on a more acceptable half-life and less propensity for significant drug-drug interactions) was stopped because of a small but statistically significant prolongation of the QT interval with high doses. Dilevalol was thought to have advantages over labetalol, but was removed from the Japanese market because of hepatotoxicity [127] .
In addition to variable pharmacodynamic properties, numerous studies have shown that the individual enantiomers of a chiral drug often display stereoselectivity in pharmacokinetics, toxicity, and drug disposition, particularly in the area of drug metabolism. Stereochemical aspects associated with the metabolism and toxicity of chiral drugs have been reported [140] . Enantiomers may result in stereoselective toxicity due to pharmacodynamic and pharmacokinetic differences between enantiomers. In toxicology, the different toxic effects of chiral drugs can reside either in one enantiomer only or in both ones. The toxicological properties in a pair of enantiomers can be identical or entirely different. They can reside in the pharmacologically active enantiomer or in the inactive one [11] . Dopa or dihydroxy-3,4 phenylalanine is a precursor of dopamine that is effective in the treatment of Parkinson disease. Dopa was used under racemic form: d,l-dopa, but owing to the grave toxicity (agranulocytosis) of d-isomer, therefore, only levoratory form called l-Dopa is actually used in therapeutics. Tetramisole is a nematocide, first used under racemic form. Because of numerous side-effects (vertigo, headache, vomiting, abdominal pain) mainly due to disomer, therefore, only l-isomer called levamisole is now used in medicine. L-(R)-carnitine is primarily used in the treatment of valproate toxicity. Neither the Disomer nor the racemate should be antidotally administered [138] . Pharmacology and toxicological effects can coexist in the same enantiomer or both. In this context, clinical superiority of escitalopram, Ralbuterol and cyclophosphamide still need to be demonstrated [140] . The R-(-) fenoprofen enantiomer is metabolically inverted to the S-(+) fenoprofen enantiomer in the liver and severe hepatic disease should alter the percentage of chiral inversion obtained for R-(-) fenoprofen. Researchers studied the chiral inversion of R-(-) fenoprofen in cats with toxic hepatic disease induced by carbon tethrachloride and the percentage of chiral inversion in animals with toxic hepatic disease was 90.5±21.1 and the difference with healthy animals was not statistically significant [141] . Interconversions occurred after the oral and i.v. administration of R-flosequinan enantiomers and Sflosequinan enantiomers [142] .
ENANTIOMERS USE IN HOMEOPATHY
Modulation of toxicity of enantiomers provides possibility for therapeutics, since they target multiple points in biochemical pathways. Inhibition of the excitotoxic neurotransmitter L-glutamic acid with homeopathic preparations of D-glutamic acid indicates the latter may be of use for amelioration of symptoms of disturbances of mood. Similarly, homeopathic preparation of (+)-nicotine may be of use for inhibition of effects of nicotine in tobacco [143] . ISOMOOD™ Homeopathic medicine contains a homeopathic formulation of D-Glutamic acid which may gently inhibit the toxic effects of a brain chemical called L-Glutamic acid, which on a molecular level is an exact mirror image of D-Glutamic acid. L-Glutamic acid is known to be involved in feelings of anxiety, nervous tension and mood swings and thus helps with anxiety treatment and stress reduction.
The toxic effects of an optical isomer may be counteracted or reversed by the administration of a potentized preparation of one of its enantiomer. Researchers concluded that toxicity of intraperitoneal injection of (-)-U50488 hydrochloride may be inhibited by administration of a mixture of potencies of its enantiomer [144] . Researchers concluded that the toxicity of intraperitoneal (-)-propranolol HCl, may be counteracted by administration of a potency of its enantiomer, in ICR conventional mice which have survived preceding intraperitoneal Rometar injection, and pre-dosing with (+)-propranolol HCl homeopathic potency [145] .
PHARMACOGENETIC ASPECTS
Pharmacogenomics refers to the general study of all of the many different genes that determine drug behaviour. Besides environmental factors, genetic factors regulate the fate of drugs in the organism. Some polymorphic enzymes such as some cytochrome P-450 isozymes display stereoselectivity toward chiral substrates or in the formation of chiral metabolites from achiral parent compounds. The pharmacogenetics of metabolism of psychotropic drugs based mainly on the study of the polymorphic enzymes CYP2D6 and CYP2C19, and the knowledge on the pharmacology, metabolism, pharmacokinetics, and pharmacogenetics of antidepressants, antipsychotics, and methadone has been reported [146] .
Genetic differences between people contribute to inter-individual differences in the response to many commonly used drugs. Pharmacogenetics primarily uses genetic variation to identify subgroups of patients who may respond differently to a certain medication and comprises of genetic studies on both the pharmacokinetics and pharmacodynamics of treatment response [147] . The pharmacogenetics of drug metabolising enzymes and particular the cytochrome P450 (CYP) enzymes has been in the focus for almost 40 years. Early experiments with debrisoquine and nortriptyline documented that patients fall into different categories: poor, intermediate, extensive and ultrarapid metabolizers. A recent study confirmed an association between CYP2D6-allele/plasma level concentrations of venlafaxine, although it did not find any such association for desvenlafaxine (an antidepre ssant of the serotonin-norepinephrine reuptake inhibitor). Desvenlafaxine is a synthetic form of the isolated major active metabolite of venlafaxine [148] . The genetically variable CYP450-mediated metabolism of a number of serotonin-active drugs that are often implicated in cases of serotonin toxicity, to assess the impact of pharmacogenetics on drug metabolism, response, interactions and adverse effects has been reported [149] A patient's response to a chiral drug is influenced by their genome, so pharmacogenetics could be used to determine drug sensitivity.
Clinically available, warfarin consists of a racemic mixture of two active optical isomers, (R)-and (S)-isoforms, and their pharmacokinetic and pharmacodynamic properties differ considerably, because the (S)-enantiomer is three times more potent than the (R)-enantiomer. There is a considerable controversy about the clinical use of genotyping before starting the anticoagulant therapy [150] . The current evidence base for pharmacogenetics in relation to drug-metabolizing enzymes was reported [151] . The relationship between pharmacokinetics and pharmacogenetics for venlafaxine and citalopram, with emphasis on enantiomeric drug disposition in different biomatrices has been reported and the CYP2D enzymes display a significant impact on the stereoselective metabolism of citalopram and venlafaxine drugs [152, 153] .
REGULATORY AFFAIRS IN SINGLE ENANTIOMERIC DRUGS
The enantiomers of a chiral drug show different pharmacokinetic and pharmacodynamic profiles. Satisfactory standards of quality, safety, and efficacy need to be demonstrated for medicines containing chiral active ingredients before they can receive an authorization to place them on the market [154] . Regulatory authorities implied guidelines that clearly state that the development of an enantiopure drug should be preferred, while it also has to be demonstrated that the developed drug is indeed enantiopure. The United States Food and Drug Administration (FDA) issued guidelines and policies in 1992 concerning the development of stereoisomeric drugs (enentiopure and racemic drugs) [155] . FDA urged the pharmaceutical industries to evaluate enantiopure drugs alongside racemic drugs as new candidates for the future. Further, world scientific and regulatories bodies (European Union, Canada, Japan) released guidelines for the development and manufacture of enantiopure drugs [156] . The regulatory review for marketing approval (safety and efficacy) and for patenting (proprietary rights) is independent, and differs country by country. Guidelines on the investigation of chiral active substances were issued by a commission of the European countries in 1994 and by Canadian Government in 2000. The importance of evaluating the behaviour of stereoisomers was further highlighted in FDA regulatory document in 2005. Based on case-to case study, the U.S. Food and Drug Administration (FDA) allowed single enantiomers of certain drugs to be marketed under a different name than the racemic mixture. Also case-by-case, the United States Patent Office has granted patents for single enantiomers of certain drugs [157] .
Chiral Separation and Patent Laws
The field of chiral separations has had a bearing on the outcome regarding the "inventiveness" of chiral drug molecules when patent law is applied [158] . Overall, all regulatory guidance recommends the investigators to identify the chirality of principle ingredient, manufacturing process, stability testing and labelling criteria of the final drug. Pharma companies have needed to make decisions whether to develop and seek protection of either the racemic mixture or the single enantiomers, or whether to pursue a chiral switching route instead by seeking to first patent the racemic drug, and then years down the road seeking to extend a drug product's life cycle by subsequently patenting the single enantiomer form of the drug [159] . On a case-by-case basis, the FDA has allowed single enantiomers of certain drugs to be marketed under a different name than the racemic mixture.
CONCLUSION AND PERSPECTIVES
There is no requirement from any regulatory authorities for marketing single isomers. However, to reduce the risk of distomer in our body, the pharmaceutical industries are looking for the development of optically pure enantiomers as chiral molecules are huge business for the pharmaceutical industry. In this direction, the increasing availability of single-enantiomer drugs promises to offer clinicians with safer, better-tolerated, and more efficacious medications for treating patients. Relatively little is known about stereochemistry concerning route of administration, dose, formulation, drug interactions, age gender, disease and genetics. The enantiomers of drugs often behave differently from each other in bioenvironment and the two enantiomers of a racemate can differ in their pharmacokinetic /pharmacodynamic and efficacy/ safety profiles. Pharmacokinetics and pharmacodynamics of chiral drugs with particular reference to bioequivalence determination should be further investigated. Continuous reevaluation should enable reintroduction of old racemates as singleenantiomer products with cleaner pharmacological profiles. In some cases, where the beneficial medical effects emerge exclusively or primarily from one enantiomer, creating a single enantiomer version of the drug can provide effective treatment with fewer side effects. These safer alternatives include levosalbutamol, Sketamine, levobupivacaine, S-zopiclone, levocetirizine, S-amlodipine, S-atenolol, S-metoprolol, S-omeprazole, S-pantoprazole and R-ondansetron, levofloxacin, dexketoprofen [160] .
Chiral switches overcome patent protection. However, chiral switching can lead to unexpected toxicity in spite of advantages such as lower therapeutic doses, more safety margin, less interindividual variability, less drug interaction, and few side effects. The higher eudismic ratio is considered as an important tool in drug discovery and drug designing and manipulation of enantiomeric composition from 1:1 ratio found in the racemate by increasing the content of active enantiomer should be further exploited to obtain improved therapeutic profile in a resulting mixture. Further, racemates should continue to be reevaluated for pharmacodynamics, pharmacokinetics, toxicological properties except in cases of rapid isomerisation within the body, and reintroduced as an enantiopure drug with improved therapeutic benefits. While pursuing scientific investigations (pharmacokinetic, pharmcodynamic, genetics or toxicologic) on handed-drugs, it is mandatory that the aspect under study be viewed from both sides of the mirror. At present, there are not many enantiopure drugs which show considerable clinical value over the racemic versions. But the enantioselective investigations viz. pK and pD studies on racemic therapeutics provide valuable information. Some examples of this approach are the development of the single enantiomer esomeprazole from the racemate omeprazole and the single enantiomer escitalopram from the racemate citalopram. Better among racemates include fluoxetine, dobutamine than enantiopure drug. In some cases (e.g., ibuprofen and thalidomide), the enantiomers interconvert or racemize in vivo. This means that preparing a pure enantiomer for medication is largely pointless.
The practicing physician should be familiar with the basic characteristics of chiral pharmaceutical. When both a single enantiomer and a racemic formulation of a drug are available, the information from clinical trials and clinical experience should be used to decide whether go for chiral switching or not. Choice of stereoisomeric form must be justified on scientific grounds. Factors influencing chiral inversion need further investigations before chiral switching.
Overall, the ultimate goal of drug development and pharmaceutical manufacturers should be to obtain superior quality medicines to make drug therapy more effective, specific and safer for the benefit of mankind. There is an urgent need for pharmacists to educate themselves regarding various issues pertaining to drug chirality and pharmacological consequences. Pharmacists should provide updated information on chiral drugs especially racemic forms to healthcare professionals to enable them to find an optimal treatment and achieve a right therapeutic control. In addition, physicians need to reassess the rationality of existing racemates and also determine the clinical value of recent enantiopure introductions.
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